The predictive markers of severity and mortality in hospitalized hemodialysis patients with COVID-19 during Omicron epidemic.

IF 1.5 4区医学 Q3 HEMATOLOGY Therapeutic Apheresis and Dialysis Pub Date : 2023-08-01 DOI:10.1111/1744-9987.13970

Masataka Banshodani, Hideki Kawanishi, Takayuki Hirai, Yusuke Kawai, Shinji Hashimoto, Sadanori Shintaku, Misaki Moriishi, Seiji Marubayashi, Shinichiro Tsuchiya

{"title":"The predictive markers of severity and mortality in hospitalized hemodialysis patients with COVID-19 during Omicron epidemic.","authors":"Masataka Banshodani, Hideki Kawanishi, Takayuki Hirai, Yusuke Kawai, Shinji Hashimoto, Sadanori Shintaku, Misaki Moriishi, Seiji Marubayashi, Shinichiro Tsuchiya","doi":"10.1111/1744-9987.13970","DOIUrl":null,"url":null,"abstract":"Introduction: Predictive markers and prognosis remain unclear in hospitalized hemodialysis (HD) patients with coronavirus disease 2019 (COVID-19) during the Omicron epidemic.Methods: We evaluated characteristics, laboratory parameters, and outcomes in hospitalized HD patients with COVID-19 (n = 102) at two centers between January and April 2022.Results: The 30-day mortality rate was higher in moderate-critical group (n = 43) than mild group (n = 59) (16.3% vs. 1.7%; p = 0.007), and higher in patients with lower CC chemokine ligand 17 (CCL17) levels (<95.0 pg/mL) compared with normal CCL17 levels (19.0% versus 4.9%; p = 0.03). In multivariate analyses, a low CCL17 level (p = 0.003) was associated with moderate-critical conditions, and moderate-critical conditions (p = 0.04) were associated with 30-day mortality, whereas CCL17 was not associated with 30-day mortality.Conclusions: COVID-19 remains a fatal complication, and CCL17 was a predictive marker of severity in hospitalized HD patients during the Omicron epidemic.","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"27 4","pages":"701-710"},"PeriodicalIF":1.5000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Apheresis and Dialysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1744-9987.13970","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: Predictive markers and prognosis remain unclear in hospitalized hemodialysis (HD) patients with coronavirus disease 2019 (COVID-19) during the Omicron epidemic.

Methods: We evaluated characteristics, laboratory parameters, and outcomes in hospitalized HD patients with COVID-19 (n = 102) at two centers between January and April 2022.

Results: The 30-day mortality rate was higher in moderate-critical group (n = 43) than mild group (n = 59) (16.3% vs. 1.7%; p = 0.007), and higher in patients with lower CC chemokine ligand 17 (CCL17) levels (<95.0 pg/mL) compared with normal CCL17 levels (19.0% versus 4.9%; p = 0.03). In multivariate analyses, a low CCL17 level (p = 0.003) was associated with moderate-critical conditions, and moderate-critical conditions (p = 0.04) were associated with 30-day mortality, whereas CCL17 was not associated with 30-day mortality.

Conclusions: COVID-19 remains a fatal complication, and CCL17 was a predictive marker of severity in hospitalized HD patients during the Omicron epidemic.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Omicron流行期间住院血液透析患者COVID-19严重程度和死亡率的预测指标

导语:在欧米克隆流行期间，2019冠状病毒病(COVID-19)住院血液透析(HD)患者的预测指标和预后尚不清楚。方法:我们评估了2022年1月至4月期间在两个中心住院的HD合并COVID-19患者(n = 102)的特征、实验室参数和结局。结果:中度危重症组(n = 43) 30天死亡率高于轻度危重症组(n = 59) (16.3% vs. 1.7%;p = 0.007)，而C - C趋化因子配体17 (CCL17)水平较低的患者则更高(结论:COVID-19仍然是一种致命的并发症，CCL17是Omicron流行期间住院HD患者严重程度的预测指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutic Apheresis and Dialysis 医学-泌尿学与肾脏学

CiteScore

3.00

自引率

10.50%

发文量

166

审稿时长

6-12 weeks

期刊介绍： Therapeutic Apheresis and Dialysis is the official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis and the Japanese Society for Dialysis Therapy. The Journal publishes original articles, editorial comments, review articles, case reports, meeting abstracts and Communications information on apheresis and dialysis technologies and treatments.